Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Zotatifin |
Trade Name | |
Synonyms | eFT226|eFT-226|eFT 226 |
Drug Descriptions |
Zotatifin (eFT226) is an eukaryotic initiation factor 4A1 (eIF4A1) inhibitor that promotes binding of eIF4A1 to the 5'-UTR in a sequence selective manner, which leads to repression of mRNA translation, including translation of the receptor tyrosine kinases FGFR1/2 and ERBB2 (HER2), and potentially results in induction of apoptosis and inhibition of tumor growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133, PMID: 32470302). |
DrugClasses | |
CAS Registry Number | 2098191-53-6 |
NCIT ID | C165746 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Fulvestrant + Zotatifin | Abemaciclib Fulvestrant Zotatifin | 0 | 1 |
Abemaciclib + Letrozole + Zotatifin | Abemaciclib Letrozole Zotatifin | 0 | 1 |
Fulvestrant + Zotatifin | Fulvestrant Zotatifin | 0 | 1 |
Sotorasib + Zotatifin | Sotorasib Zotatifin | 0 | 1 |
Trastuzumab + Zotatifin | Trastuzumab Zotatifin | 0 | 1 |
Zotatifin | Zotatifin | 2 | 1 |